Some New Hydrazone Derivatives Bearing the 1,2,4-Triazole Moiety As Potential Antimycobacterial Agents

Overview

Journal Turk J Pharm Sci

Specialty Pharmacology

Date 2020 May 27

PMID 32454746

Citations 1

Authors

Keriman Ozadali Sari

Oya Unsal Tan

Dharmarajan Sriram

Ayla Balkan

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to synthesize, characterize, and screen some new 1-(4-((2-(4-substitutedphenyl)hydrazono)methyl)phenyl)-1H-1,2,4-triazole derivatives for their antimycobacterial activities.

Materials And Methods: The target compounds were gained by condensation of 4-(1-1,2,4-triazol-1-yl)benzaldehyde with appropriate phenylhydrazines. Their structures were elucidated by IR, H-NMR, and mass spectrometry. The antimycobacterial activities of the compounds were determined against H37Rv.

Results: The biological assay results showed that the methylsulfonyl-substituted derivative displayed the highest antimycobacterial activity in this series.

Conclusion: Although the methylsulfonyl-substituted derivative exhibited significant antimycobacterial activity, none of the synthesized compounds was as effective as isoniazid, rifampin, ethambutol, and ciprofloxacin against .

Citing Articles

Novel Hybrid 1,2,4- and 1,2,3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking.

El Sawy M, Elshatanofy M, El Kilany Y, Kandeel K, Elwakil B, Hagar M Int J Mol Sci. 2022; 23(9).

PMID: 35563096 PMC: 9103244. DOI: 10.3390/ijms23094706.

References

Kumar K, Abubakar I . Clinical implications of the global multidrug-resistant tuberculosis epidemic. Clin Med (Lond). 2015; 15 Suppl 6:s37-42. DOI: 10.7861/clinmedicine.15-6-s37. View

Meciarova M, Toma S, Magdolen P . Ultrasound effect on the aromatic nucleophilic substitution reactions on some haloarenes. Ultrason Sonochem. 2003; 10(4-5):265-70. DOI: 10.1016/S1350-4177(02)00157-8. View

Saltini C . Chemotherapy and diagnosis of tuberculosis. Respir Med. 2006; 100(12):2085-97. DOI: 10.1016/j.rmed.2006.09.015. View

Collins L, Franzblau S . Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother. 1997; 41(5):1004-9. PMC: 163841. DOI: 10.1128/AAC.41.5.1004. View

Ahmad Z, Sharma S, Khuller G, Singh P, Faujdar J, Katoch V . Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents. 2006; 28(6):543-4. DOI: 10.1016/j.ijantimicag.2006.07.028. View

Cochrane J, White J, Wille U, Hutton C . Total synthesis of mycocyclosin. Org Lett. 2012; 14(9):2402-5. DOI: 10.1021/ol300831t. View

Kuaban C, Noeske J, Rieder H, Ait-Khaled N, Foe J, Trebucq A . High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015; 19(5):517-24. DOI: 10.5588/ijtld.14.0535. View

Franke M, Becerra M, Tierney D, Rich M, Bonilla C, Bayona J . Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc. 2015; 12(5):674-9. PMC: 4418338. DOI: 10.1513/AnnalsATS.201411-538OC. View

Wallis R, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori G . Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis. 2016; 16(4):e34-46. DOI: 10.1016/S1473-3099(16)00070-0. View

10.

Jones D . Tuberculosis success. Nat Rev Drug Discov. 2013; 12(3):175-6. DOI: 10.1038/nrd3957. View

11.

Savini L, Chiasserini L, Gaeta A, Pellerano C . Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones. Bioorg Med Chem. 2002; 10(7):2193-8. DOI: 10.1016/s0968-0896(02)00071-8. View

12.

Hoagland D, Liu J, Lee R, Lee R . New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev. 2016; 102:55-72. PMC: 4903924. DOI: 10.1016/j.addr.2016.04.026. View

13.

Tiberi S, Scardigli A, Centis R, DAmbrosio L, Munoz-Torrico M, Salazar-Lezama M . Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 2016; 56:181-184. DOI: 10.1016/j.ijid.2016.10.026. View

14.

Kaymakcioglu B, Aktan Y, Suzen S, Gokhan N, Koyunoglu S, Erol K . In vivo metabolism of 2-[1'-phenyl-3'-(3-chlorophenyl)-2'-propenylyden]hydrazino-3-methyl-4(3H)-quinazolinone in rats. Eur J Drug Metab Pharmacokinet. 2006; 30(4):255-60. DOI: 10.1007/BF03190629. View

15.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T . Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2012; 41(6):1393-400. PMC: 3669462. DOI: 10.1183/09031936.00125812. View

16.

Ahmad S, Mokaddas E . Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health. 2013; 7(2):75-91. DOI: 10.1016/j.jiph.2013.09.001. View

17.

Kocyigit-Kaymakcioglu B, Unsalan S, Kucukguzel S, Sener G, Rollas S . HPLC analysis of in vivo metabolites of 4-nitrobenzoic acid [(5-nitro-2-thiopheneyl)methylene]hydrazide in rats. Eur J Drug Metab Pharmacokinet. 2008; 32(4):197-203. DOI: 10.1007/BF03191004. View

18.

Gulerman N, Oruc E, Kartal F, Rollas S . In vivo metabolism of 4-fluorobenzoic acid [(5-nitro-2-furanyl)methylene] hydrazide in rats. Eur J Drug Metab Pharmacokinet. 2000; 25(2):103-8. DOI: 10.1007/BF03190075. View

19.

Van Deun A, Maug A, Salim M, Das P, Sarker M, Daru P . Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182(5):684-92. DOI: 10.1164/rccm.201001-0077OC. View

20.

Podust L, Poulos T, Waterman M . Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci U S A. 2001; 98(6):3068-73. PMC: 30608. DOI: 10.1073/pnas.061562898. View